MX2023001285A - Metodos para reducir la concentracion de glicoesfingolipidos en el tejido cerebral y metodos de tratamiento de enfermedades neurodegenerativas que implican los mismos. - Google Patents
Metodos para reducir la concentracion de glicoesfingolipidos en el tejido cerebral y metodos de tratamiento de enfermedades neurodegenerativas que implican los mismos.Info
- Publication number
- MX2023001285A MX2023001285A MX2023001285A MX2023001285A MX2023001285A MX 2023001285 A MX2023001285 A MX 2023001285A MX 2023001285 A MX2023001285 A MX 2023001285A MX 2023001285 A MX2023001285 A MX 2023001285A MX 2023001285 A MX2023001285 A MX 2023001285A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- brain tissue
- treatment
- same
- neurodegenerative diseases
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 6
- 210000005013 brain tissue Anatomy 0.000 title abstract 3
- 150000002339 glycosphingolipids Chemical class 0.000 title abstract 2
- 238000011282 treatment Methods 0.000 title abstract 2
- 230000004770 neurodegeneration Effects 0.000 title 1
- 208000015122 neurodegenerative disease Diseases 0.000 title 1
- 102100033342 Lysosomal acid glucosylceramidase Human genes 0.000 abstract 3
- 101000997662 Homo sapiens Lysosomal acid glucosylceramidase Proteins 0.000 abstract 2
- 230000035772 mutation Effects 0.000 abstract 2
- 101150084750 1 gene Proteins 0.000 abstract 1
- 206010067889 Dementia with Lewy bodies Diseases 0.000 abstract 1
- 108010017544 Glucosylceramidase Proteins 0.000 abstract 1
- 201000002832 Lewy body dementia Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 230000008482 dysregulation Effects 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000008584 quinuclidines Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063059047P | 2020-07-30 | 2020-07-30 | |
| US202063131120P | 2020-12-28 | 2020-12-28 | |
| PCT/IB2021/056971 WO2022024062A1 (en) | 2020-07-30 | 2021-07-30 | Methods for reducing glycosphingolipid concentration in brain tissue and methods of treatment of neurodegenerative diseases involving the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023001285A true MX2023001285A (es) | 2023-02-22 |
Family
ID=77265125
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023001285A MX2023001285A (es) | 2020-07-30 | 2021-07-30 | Metodos para reducir la concentracion de glicoesfingolipidos en el tejido cerebral y metodos de tratamiento de enfermedades neurodegenerativas que implican los mismos. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230372313A1 (https=) |
| EP (1) | EP4188381A1 (https=) |
| JP (1) | JP2023535483A (https=) |
| KR (1) | KR20230047146A (https=) |
| CN (1) | CN116322679A (https=) |
| AU (1) | AU2021317180A1 (https=) |
| BR (1) | BR112023001362A2 (https=) |
| CA (1) | CA3187086A1 (https=) |
| IL (1) | IL300096A (https=) |
| MX (1) | MX2023001285A (https=) |
| WO (1) | WO2022024062A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114040762A (zh) | 2019-02-04 | 2022-02-11 | 建新公司 | 使用葡糖神经酰胺合酶(gcs)的抑制剂治疗纤毛疾病 |
| KR20260021150A (ko) | 2024-08-05 | 2026-02-13 | 충북대학교 산학협력단 | Gba1 돌연변이 보인자의 dj-1 발현수준에 따른 파킨슨병의 위험도 예측 방법 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| KR101987736B1 (ko) * | 2011-03-18 | 2019-06-11 | 젠자임 코포레이션 | 글루코실세라마이드 합성효소 억제제 |
| JO3713B1 (ar) | 2013-03-15 | 2021-01-31 | Genzyme Corp | أشكال ملح (s)-كوينوكليدين-3-يل(2-(2-(4-فلوروفينيل)ثيازول-4-يل)بروبان-2-يل)كارباميت |
| TW201642855A (zh) | 2015-03-10 | 2016-12-16 | 健臻公司 | 用於治療蛋白質病變之方法 |
| US10617713B2 (en) * | 2016-03-08 | 2020-04-14 | Neurocentria, Inc. | Methods of modifying neuronal function by changing intracellular magnesium levels |
| EP3452045A1 (en) * | 2016-05-04 | 2019-03-13 | Lysosomal Therapeutics Inc. | Methods of treatment and combination therapies using gcase activator heterobicyclic and related compounds |
| US10519157B2 (en) * | 2018-02-09 | 2019-12-31 | X-Cutag Therapeutics, Inc. | Deuterated compounds for treating Fabry, Gaucher, Parkinson's and related diseases and conditions, and compositions and methods thereof |
-
2021
- 2021-07-30 US US18/007,433 patent/US20230372313A1/en active Pending
- 2021-07-30 CA CA3187086A patent/CA3187086A1/en active Pending
- 2021-07-30 EP EP21752208.5A patent/EP4188381A1/en active Pending
- 2021-07-30 WO PCT/IB2021/056971 patent/WO2022024062A1/en not_active Ceased
- 2021-07-30 BR BR112023001362A patent/BR112023001362A2/pt unknown
- 2021-07-30 CN CN202180065014.XA patent/CN116322679A/zh active Pending
- 2021-07-30 AU AU2021317180A patent/AU2021317180A1/en active Pending
- 2021-07-30 MX MX2023001285A patent/MX2023001285A/es unknown
- 2021-07-30 JP JP2023505841A patent/JP2023535483A/ja active Pending
- 2021-07-30 KR KR1020237007140A patent/KR20230047146A/ko active Pending
- 2021-07-30 IL IL300096A patent/IL300096A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022024062A1 (en) | 2022-02-03 |
| CN116322679A (zh) | 2023-06-23 |
| EP4188381A1 (en) | 2023-06-07 |
| JP2023535483A (ja) | 2023-08-17 |
| BR112023001362A2 (pt) | 2023-02-14 |
| IL300096A (en) | 2023-03-01 |
| AU2021317180A1 (en) | 2023-03-23 |
| US20230372313A1 (en) | 2023-11-23 |
| KR20230047146A (ko) | 2023-04-06 |
| CA3187086A1 (en) | 2022-02-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0712322A2 (pt) | compostos e combinações destes para a inibição da produção de beta-amilóide e métodos de uso dos mesmos | |
| PH12012501480A1 (en) | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| MX2011007854A (es) | Metodos para tratar infartos agudos al miocardio y trastornos relacionados. | |
| EP2331095A4 (en) | CYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF | |
| MX2021011563A (es) | Derivados de 2,3-dihidro-isoindol-1-ona, como inhibidores de la btk quinasa y composiciones farmaceuticas que los incluyen. | |
| BR112014015482A8 (pt) | compostos carbamato de fenila para uso no alívio ou tratamento de dor e dor neuropática | |
| PH12021553223A1 (en) | IMIDAZO[1,2-a]PYRIDINYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | |
| MX2023001285A (es) | Metodos para reducir la concentracion de glicoesfingolipidos en el tejido cerebral y metodos de tratamiento de enfermedades neurodegenerativas que implican los mismos. | |
| CL2023000296A1 (es) | Uso de dexpramipexol para el tratamiento del asma moderado a grave | |
| CA2986891C (en) | Compositions for use in treating parkinson's disease and related disorders | |
| MX2024014117A (es) | Sales de ácido piperidinil-metil-purina-amina-d-tartárico, formas cristalinas y su uso en el tratamiento de enfermedades y condiciones médicas | |
| MX2023000610A (es) | Inhibidor de trpv4 como agente terapeutico para enfermedades oculares. | |
| WO2010018996A3 (ko) | 인간 신경줄기세포 및 이를 이용한 중추 또는 말초 신경계 질환 및 손상 치료용 약학적 조성물 | |
| WO2023081482A9 (en) | Combination of a bile acid and a phenyl butyrate compound for the treatment of neurodegenerative diseases | |
| EP1628663A4 (en) | METHOD FOR REDUCING AMYLOID DEPOSITION, AMYLOID NEUROTOXICITY AND MICROGLIOSIS | |
| MY205498A (en) | Ophthalmic topical composition comprising dobesilic acid for treating diseases of the posterior segment of the eye | |
| WO2014047288A3 (en) | Transglutaminase tg2 inhibitors, pharmaceutical compositions, and methods of use thereof | |
| UA109359C2 (xx) | Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном | |
| EA202193211A1 (ru) | Лечение синуклеопатий | |
| MX2024007043A (es) | Purinas y métodos de uso. | |
| Kc et al. | Practical aspects in topical PUVAsol in dermatology: An experience in a teaching hospital | |
| MX2024007010A (es) | Pirimidinas y metodos para su uso. | |
| US10076520B2 (en) | Use of tyrosine kinase inhibitor in cancer treatment | |
| EP1455771B1 (en) | 2-indanylamino derivatives for the therapy of chronic, acute or inflammatory pain | |
| BR0317772A (pt) | Método de tratamento de um distúrbio de comportamento, uso de um composto, e, agente terapêutico para um distúrbio de comportamento |